Vanda Pharmaceuticals (VNDA) closed the latest trading day at $4.06, indicating a -1.46% change from the previous session's end. This change lagged the S&P 500's daily loss of 1.2%. On the other ...

Vanda Pharmaceuticals (VNDA) ended the recent trading session at $4.28, demonstrating a -1.83% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Mihael Hristos Polymeropoulos, the President and CEO of $VNDA, bought 10,000 shares of the company on 02-25-2025 for an estimated $44,640. This trade was reported by ...

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda (VNDA – Research Report) on February 14 and set a price target of $20.00. The company’s shares closed last Friday at $4.42.

Vandana Singh VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the FDA issued a complete response letter to its new ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...